Tyme Technologies, Inc.

NasdaqCM:TYME Rapport sur les actions

Capitalisation boursière : US$53.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tyme Technologies Gestion

Gestion contrôle des critères 3/4

Informations clés

Richie Cunningham

Directeur général

US$1.3m

Rémunération totale

Pourcentage du salaire du PDG41.97%
Durée du mandat du directeur général1.8yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction2.7yrs
Durée moyenne du mandat des membres du conseil d'administration6.1yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Sep 15

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Shareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
Article d'analyse • Aug 05

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05

TYME stock surges on merger agreement and Syros Pharmaceuticals

Development stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Article d'analyse • Mar 19

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 07

Tyme Technologies Offers Incredible Risk-Reward

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
Article d'analyse • Nov 19

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 27

Tyme Technologies: The Market Missed The Bullish Memo

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Article d'analyse • Jul 19

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d'analyse • Mar 26

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Article d'analyse • Feb 19

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Article d'analyse • Feb 02

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Article d'analyse • Dec 16

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
Article d'analyse • Dec 09

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyse de la rémunération des PDG

Comment la rémunération de Richie Cunningham a-t-elle évolué par rapport aux bénéfices de Tyme Technologies?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2022n/an/a

-US$24m

Mar 31 2022US$1mUS$564k

-US$24m

Dec 31 2021n/an/a

-US$24m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021US$2mUS$194k

-US$29m

Rémunération vs marché: La rémunération totale de Richie ($USD 1.34M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 622.00K ).

Rémunération et revenus: La rémunération de Richie a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Richie Cunningham (51 yo)

1.8yrs
Titularisation
US$1,344,080
Compensation

Mr. Richard Cunningham, also known as Richie, serves as Chief Executive Officer and Director at Tyme Technologies, Inc. since November 23, 2020. Mr. Cunningham had been the Chief Executive Officer and Pres...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Richard Cunningham
CEO & Director1.8yrsUS$1.34mpas de données
Steven Hoffman
Co-Founder & Director9.2yrsUS$2.60m11.63%
$ 6.2m
Frank Porfido
Chief Financial Officer1.3yrsUS$1.29m0.0058%
$ 3.1k
James Biehl
Chief Legal Officer & Secretary4yrsUS$1.19m0.061%
$ 32.7k
Jonathan Eckard
Chief Business Officer3.5yrsUS$858.79kpas de données
Jan Van Tornout
Acting Chief Medical Officer1.4yrspas de données0.0057%
$ 3.1k
2.7yrs
Durée moyenne de l'emploi
58yo
Âge moyen

Gestion expérimentée: L'équipe de direction de TYME est considérée comme expérimentée (ancienneté moyenne 2.7 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Richard Cunningham
CEO & Director1.8yrsUS$1.34mpas de données
Steven Hoffman
Co-Founder & Director7.5yrsUS$2.60m11.63%
$ 6.2m
Timothy Tyson
Independent Director7.5yrsUS$138.73k0.0034%
$ 1.8k
Donald DeGolyer
Independent Director4.3yrsUS$146.99kpas de données
Douglas Michels
Independent Chairman3.9yrsUS$166.34k0.064%
$ 34.2k
David Carberry
Independent Director5.5yrsUS$148.24k0.058%
$ 31.1k
Gerald Sokol
Independent Director & Member of Medical Advisory Board7.5yrsUS$122.87k0.0034%
$ 1.8k
Suresh Chari
Member of Medical Advisory Board6.7yrspas de donnéespas de données
Paul Oberstein
Member of Medical Advisory Boardno datapas de donnéespas de données
Marcus Noel
Member of Medical Advisory Boardno datapas de donnéespas de données
Allyson Ocean
Member of Medical Advisory Boardno datapas de donnéespas de données
Vincent Picozzi
Member of Medical Advisory Boardno datapas de donnéespas de données
6.1yrs
Durée moyenne de l'emploi
65yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TYME sont considérés comme expérimentés (ancienneté moyenne 6.1 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2022/09/16 08:35
Cours de l'action en fin de journée2022/09/16 00:00
Les revenus2022/06/30
Revenus annuels2022/03/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Tyme Technologies, Inc. est couverte par 3 analystes. de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Arlinda LeeCanaccord Genuity
Joshua SchimmerEvercore ISI
Swayampakula RamakanthH.C. Wainwright & Co.